Heart rate reduction with ivabradine is associated with improved health-related quality of life.
The magnitude of heart rate reduction is related to the extent of improvement in health-related quality of life.¹


Ivabradine or placebo on top of guideline-recommended therapy including
ACE inhibitor, β-blocker, mineralocorticoid receptor antagonist.

1. Ekman I, et al. Eur Heart J. 2011;32(19):2395-2404.

you want to know more …

on the positive change with ivabradine in KCCQ subscores at 1 year1